YESCARTA™ for Lymphoma Treatment

The FDA recently approved the use of the YESCARTA CAR T-cell therapy for treatment of non-Hodgkin lymphoma. The University of Kansas Cancer Center – one of just 69 National Cancer Institute-designated cancer centers in the country – is among the first sites selected to offer this groundbreaking immunotherapy treatment.

YESCARTA – axicabtagene ciloleucel for adult patients with refractory, aggressive non-Hodgkin lymphoma – is a revolutionary form of precision medicine. Personalized for each patient, it is made from the individual’s own white blood cells. These T cells are extracted from the body, modified in a manufacturing center, and then returned to the body, reengineered to recognize and destroy cancer cells. 

As home to the region’s largest and most experienced blood and marrow transplant (BMT) and cellular therapeutics program, The University of Kansas Cancer Center is uniquely qualified to serve as one of the first providers of YESCARTA treatment. Our multidisciplinary care team is highly versed in the specific needs of patients with blood disorders and the care options and risks involved in treating them. We offer the significant infrastructure required to deliver and manage this complex treatment. 

Our BMT program offers more than 40 years of leadership and compassionate care and has exhibited 800 percent growth in the last decade. It represents a powerful foundation on which to advance expertise as immunotherapy increasingly takes its position among frontline cancer treatment options. 

We are pleased to provide resources to help inform you as you explore this critical possibility in your cancer care and to earn your confidence as you consider our team and program. 

Request an Appointment


Toll Free


Clinical Trials

Clinical trials can give you access to potentially effective new drugs, therapies and diagnostic tools in research.

Let us match you to an open trial. Contact our clinical trials nurse navigator, 913-945-7552.